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ABSTRACT
Objectives: This study  investigates the estrogen-like effects of 
resveratrol (RES) in female rats. 
Materials and Methods:  In this two-step study on estrogen-
like activity of RES, immature female rats (21 days old) were used 
in the first step and pubertal female rats (28 days old) with primary 
ovarian failure (POF) induced by 4-vinylcyclohexene diepoxide 
(VCD) were used in the second step. Possible agonistic and/or 
antagonistic effects of RES were investigated by using several 
parameters including the ratios of uterine/body weights (UBW), 
uterine dry/wet weights (UDWW) and body weight increase 
(BW%), bone density measurement, serum estradiol and vitamin 
D levels and histological evaluation. 
Results: In immature rats, RES resulted in an increase in UBW 
equal to that produced by  17 alpha-ethinyl estradiol (17alphaEE). 
The minimum effective dose for RES was 10 mg/kg. This effect 
was not decreased by tamoxifen but was significantly antagonized 
by fulvestrant. Similarly, tamoxifen did not abolish the effects of 
RES completely in rats with POF.  However, in rats with VCD-
induced POF, tamoxifen resulted in lower UBW values and 
estradiol levels  were significantly higher in 17alphaEE-treated, 
RES+tamoxifen-treated and 17 beta-estradiol (17betaE)-treated 
rats compared to control animals.
Conclusion: The dose of RES may be important in terms of 
estrogenic activity and even RES may modulate the effects of 
estrogen.
Keywords:  Estrogen, Resveratrol,  4-vinylcyclohexene diepoxide, 
Primary ovarian failure 
ÖZ
Amaç: Çalışmamızda resveratrol (RES)’ün dişi sıçanlarda 
oluşturduğu estrojenik etkilerin incelenmesi amaçlanmıştır. 
Gereç ve Yöntem: Çalışmamızın ilk aşamasında, 
RES’ün,  immatür (21 günlük) dişi sıçanlarda, 2. aşamasında 
4-vinilsiklohekzen diepoksid (VCD) enjeksiyonu ile primer over 
yetmezliği (POY) oluşturulan puberte dönemindeki (28 günlük) dişi 
sıçanlarda oluşturduğu estrojenik etkileri incelenmiştir. RES’ün 
agonist ve/veya antagonist etkileri çeşitli parametreler kullanılarak 
araştırılmıştır. Bu parametreler uterus ağırlığı/vücut ağırlığı 
oranları(UA/VA), uterus kuru ağırlığı/uterus yaş ağırlığı oranları 
(UKA/UYA), VA artış oranları, kemik dansitometresi, serum 
estradiol ve vitamin D değerleri ve histolojik değerlendirmedir. 
Bulgular: İmmatür sıçanlarda UA/VA oranları 
değerlendirmesinde RES, UA/VA oranını 17 alfa-etinil estradiol 
(17alfaEE)’e benzer bir şekilde arttırmıştır. En düşük anlamlı 
etki 10 mg/kg RES dozunda görülmüştür. Bu etki tamoksifen ile 
azalmazken fulvestrant ile anlamlı bir şekilde antagonize edilmiştir. 
POY oluşturulmuş dişi sıçanlarda da tamoksifen,  RES’ün etkilerini 
tamamen ortadan kaldırmamıştır. UA/VA değerleri açısından 
POY geliştirilmiş sıçanlarda VCD+RES10mg/kg+tamoksifen 
verilen grubun ortalama değerlerinin, VCD+RES 10mg/kg verilen 
grubun ortalama değerlerinden daha düşüktür. POY geliştirilmiş 
sıçanlarda estradiol değerleri incelendiğinde, VCD+17alfaEE, 
sıçanlarda VCD+RES 10mg/kg+tamoksifen ve VCD+17 beta-
estradiol (17betaE) verilen gruplarda estradiol değerlerinin kontrol 
değerlerine göre anlamlı derecede arttığı gözlenmektedir. 
Sonuç: Çalışmamızın sonucuna göre estrojenik aktivite 
açısından RES’ün dozu önemli bir faktör olabilir ve RES’ün 
estrojen modülatörü olarak etki ettiği söylenebilir.
Anahtar kelimeler: Estrojen, Resveratrol, 4-vinilsikloheksen 
diepoksid, Primer over yetmezliği 
Introduction
Resveratrol (trans-3,5,4’-trihydroxystilbene) (RES) is a 
natural polyphenol that is synthesized as a phytoalexin 
by the herbals. It is found abundantly in several foods 
including grapes, berries, nuts and red wine. It is well 
known that RES has many pharmacological effects such as 
antioxidant, antiinflammatory, analgesic, cardioprotective, 
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neuroprotective, antiaging [1,2] and antitumoral  activities 
[3]. RES is also known as a phytoestrogen. RES was reported 
to bind to estrogen receptors and compete with 17 beta-
estradiol (17betaE) in vitro [2,4]. Because of the structural 
similarity of RES and diethylstilbestrol, a synthetic estrogen, 
it was postulated that RES may have an estrogenic activity. 
However, it is controversial that whether resveratrol is 
an estrogen agonist or antagonist. While several authors 
suggested that RES has an estrogenic activity [4,5], others 
noted an antiestrogenic activity [6,7].
In the present study, we investigated the putative 
estrogenic effects of RES on uterine growth in a female 
immature (21 days old) rat model, which is a widely 
accepted model for the studies of in vivo estrogen agonistic 
and/or antagonistic effects [5,8]. In the second step, the 
estrogenic activity was investigated in pubertal female rats 
(28 days old) with primary ovarian failure (POF) induced by 
4-vinylcyclohexene diepoxide (VCD) [9,10]. Uterine growth 
and differentiation, ovarian differentiation, body weight, 
bone densitometry and serum levels of estradiol and vitamin 
D were evaluated. In vivo effects of RES were compared 
with those of 17 alpha-ethynyl estradiol (17alphaEE) and 
17betaE.
Materials and Methods
Sprague-Dawley female rats, used in all studies, were 
supplied by the Medical and Surgical Experimental Research 
Center of Eskisehir Osmangazi University. All animals 
had free access to water and a pelleted commercial diet. 
The experiments were conducted in accordance with the 
protocol approved by the Animal Care and Use Committee 
of Eskisehir Osmangazi University. 
Immature female rat study
Twenty-one days-old Sprague-Dawley female rats weighing 
approximately 35-40 g were treated by oral gavage with 
either vehicle (%20 Dimethyl sulfoxide (DMSO) (Sigma- 
Aldrich, St. Louis, MO,USA)/water), RES (Sigma- Aldrich, 
St. Louis, MO, USA) at doses of 2, 10 or 20 mg/kg/day 
(RES2, RES10, RES20), or 17alphaEE (Sigma- Aldrich, St. 
Louis, MO,USA) at a dose of 30 µg/kg/day [11]  for  3 days. 
Tamoxifen (TMX) (Sigma- Aldrich, St. Louis, MO, USA) 
(2 µg/kg/day) and fulvestrant (FLV) (Sigma- Aldrich, St. 
Louis, MO,USA)  (5 mg/kg/day) were used as estrogenic 
antagonists. Animals were divided into 10 groups with 
six animals in each: Control, 17alfa-EE, RES2, RES10, 
RES20, RES2+17alfaEE, RES10+TMX, RES10+FLV, 
17alfaEE+TMX, 17alfaEE+FLV. Because it was pre-
determined to use the minimum effective dose for RES in 
groups treated with FLV and TMX, 10 mg/kg RES was co-
administered with FLV- and TMX-treated groups. 
The overnight-fasted rats were weighed 24 hours after 
the final dose and 1 ml of blood was withdrawn by cardiac 
puncture under the ether anesthesia and collected into dry 
tubes. Serum samples obtained by centrifugation were 
stored at -40oC until analysis. The animals were sacrificed 
by an overdose of anesthesia and autopsied. After the 
measurement of uterine wet weight, the uterus was cut into 
two pieces. One of them weighed again, placed on stainless 
steel drying shelf in an oven at 60 oC for 12 hours and the 
uterine dry weight was measured.  The other part of the 
uterus was used for histological analysis.
Peripubertal female rat with primary ovarian failure 
study
28 days-old Sprague-Dawley female rats weighing 40-50 
g were used in this step. A total of 6 groups containing 6 
animals in each were used: Control, VCD, VCD+17alfaEE, 
VCD+RES10, VCD+RES10+TMX, VCD+17betaE. Only 
the minimum effective RES dose (10 mg/kg/day) pre-
determined in immature female rat study was used in this 
step of the study. VCD (Fluka, Buchs, Switzerland) was 
dissolved in DMSO and injected to the animals at a dose of 
60 mg/kg/day for 15 days [9,12].  Twenty-four hours after 
the last injection, RES at a dose of 10 mg/kg/day (the dose 
that exerted least estrogenic activity in immature female 
rat study) 17 alpha-EE at a dose of 30 µg/kg/day [11] or 
17betaE (Sigma- Aldrich, St. Louis, MO,USA) at a dose of 
0.4 mg/kg/day [13] was given to the animals by oral gavage 
for 3 days. TMX (2 µg/kg/day) and FLV (5 mg/kg/day) were 
also used as estrogenic antagonists. DMSO was given to the 
control animals. Sample collection and other procedures 
were same as the first step.
Morphometrical evaluations
The ratios of uterine wet weight to body weight (UW/BW; 
mg/g) and uterine dry weight to uterine wet weight (UDW/
UWW; g/g), and the percentage of body weight increase 
[(BW on the last day - BW on the first day of the experiment) 
x100/ BW on the first day] were calculated.
Uterine and ovarian histology
Formaline-fixed uteri and ovaries were used for conventional 
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paraffin embedding process. Sections of about 3-µm 
thickness were cut from each block. Slides were stained 
with hemotoxylin and eosin before undergoing image 
analysis for measurement of the endometrial epithelium and 
myometrial thicknesses. Samples were evaluated by using a 
light microscope (Olympus U-PM-TVC) and pictures were 
taken with Olympus Q color 3 digital camera.
The thickness of endometrial epithelium was measured. 
Increase in the endometrial epithelium thickness, 
hypertrophy in the uterus, increase in mitotic cell numbers, 
spindle-shaped cells underlying basal lamina and cells with a 
dark nuclei were considered as signs of increased estrogenic 
activity. On the other hand, decreased endometrial epithelium 
thickness, cubical shape in epithelial cells, round-shaped 
cells underlying basal lamina, cells with  round nuclei and 
atrophic appearance of the uterus were considered as the 
antagonistic characteristics of substances (Fig. 1).
Fig. 1. The histological images of the uteri of immature female rats 
(a)Control, (b)17 alpha EE, (c)RES 2+17 alpha EE, (d)17 alpha EE +TMX, 
(e)RES 10 +TMX, (f)RES 10 +FLV X 400 
Follicles in the ovary were examined. Decreased or 
increased number of primary and primordial follicles 
compared to the control group was considered as ovarian 
failure or estrogenic activity, respectively (Fig. 2). All 
histological analysis was performed by a histologist blinded 
to the groups. 
Fig. 2. The histological images of the ovaries of peripubertal 
female rats with POF
(a)Control, (b)VCD, (c)VCD +17 alpha EE, (d)VCD+RES 10, (e)
VCD+RES10+TMX, (f)VCD+17 beta E X 400 
Bone mineral density  measurements
The right femur of rats with POF was removed during 
autopsy and scanned ex vivo using DEXA scanner (Norland 
XR-46, Norland Corp, Fort Atkinson,VI) equipped with a 
software to be used in measurements on small-sized animals. 
Resolution of scanning was 0.5x0.5 cm and rate of scanning 
was 60 mm/sec.
Serum estradiol and vitamin D analysis
The serum concentration of estradiol was determined by 
enzyme immunoassay, using a commertially available 
kit (Estradiol EIA Kit. Cayman Chemical Company,Ann 
Arbor,USA)  Serum 25-hydroxy vitamin D levels were 
determined in rats with POF with a commercially available 
ELISA kit (Immunodiagnostic Systems Limited, Boldon, 
UK).
Statistical analysis
The data were expressed as mean±SD. Significance 
was determined by one way ANOVA test and multiple 
comparison test of TUKEY. P values of <0.05 were 
considered to be statistically significant. 
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Results 
There were no significant differences in body weight gains 
of the immature animals.  RES increased the UW/BW in 
a dose-dependent manner, with no significant difference 
between the doses of 10 mg/kg and 20 mg/kg. The activity 
observed with 10 mg/kg resveratrol was equal to that 
produced by 17alphaEE. The increases in UW/BW were 
inhibited insignificantly with the addition of TMX but 
significantly with the addition of FLV (p<0.001)  (Fig. 3). 
The ratio of uterine dry weight/wet weight in all groups was 
not different from the control group except the combination 
with FLV. Combination of 17alphaEE and FLV significantly 
increased the UDW/UWW  (Fig. 4).
Fig. 3. Ratio of uterus weight/body weight in immature female rats 
(n=6)
(*)=Different from control, (*)=p<0.05, (**)=p<0.01 
(+)=Different from Resveratrol (10mg/kg) (RES10), (+++)=p<0.001
(^)=Different from17alpha ethynyl estradiol (17alpha EE), (^^^)=p<0.001
(&)=Different from Res10+tamoxifen (TMX), (&&)=p<0.01, 
(&&&)=p<0.001
Fig. 4. Ratio of uterus dry weight /wet weight in immature female 
rats (n=6)
(*)=Different from control, (*)=p<0.05        
(^)=Different from 17alphaEE, (^^^)=p<0.001 
Endometrial thickness was significantly increased in 
17alphaEE and 17alphaEE + TMX groups (p<0.001) and also 
in RES10 (p<0.01) and RES20 (p<0.001) groups compared 
to the control group.
 
RES increased the endometrial thickness 
in a dose-dependent manner. However, these effects of RES 
at all three doses were significantly lower than that of 17 
alphaEE (p<0.001). Endometrial thickness was significantly 
decreased in 17alphaEE+FLV and RES10+FLV groups 
(p<0.001) compared to the control group, indicating the 
antagonistic effect of FLV.
Endometrial thickness was also significantly increased 
in RES2+17alphaEE group compared to the control and 
17alphaEE groups (p<0.001), but was quite similar between 
RES10+TMX and control groups.
17alphaEE (p<0.001) and RES at the doses of 10 mg/
kg (p<0.01) or 20 mg/kg (p<0.001) significantly increased 
endometrial thickness in immature rats (p<0.001). FLV but 
not TMX inhibited these effects of 17alphaEE and RES10 
(p<0.001) (Fig. 5). Interestingly, RES2 inhibited the effects 
of 17alphaEE (p<0.001) on the endometrial thickness (Figs. 
1, 5).  Serum estradiol levels was inhibited significantly by 
RES20 (p<0.05) as compared to 10 mg/kg in immature rats 
group (Fig. 6).
Fig. 5. Histological scores of immature female rats (Based on en-
dometrial thickness) (n=6)
(*)=Different from control, (**)=p<0.01, (***)=p<0.001
(^)=Different from 17 alpha EE,  (^^^)=p<0.001
(+)=Different from Res10, (++)=p<0.01, (+++)=p<0.001
(&)=Different from Res10+TMX, (&&&)=p<0.001
Fig. 6. Serum estradiol levels in immature female rats (n=6).
(+)=Different from RES10, (+)=p<0.05 
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Primary ovarian failure  groups
VCD significantly decreased UW/BW (p<0.01). 17alphaEE 
did not reversed this effect but RES10 (p<0.05) and 17betaE 
(p<0.01)  significantly reversed the effects of VCD. (Fig. 7). 
But no significant differences were observed in UDW/UWW 
in none of the VCD-treated groups. RES10 and 17betaE 
significantly increased the percentage of body weight  and 
TMX did not reverse these effects of RES (Fig. 8).
Fig. 7. Ratio of uterus weight/body weight  in peripubertal female 
rats with POF (n=6)
(*)=Different from control, (*)=p<0.05, (**)=p<0.01
(x)=Different from VCD, (x)=p<0.05, (xx)=p<0.01
Fig. 8. Percentage of body weight increase in peripubertal female 
rats with POF (n=6)
(*)=Different from control, (*)=p<0.05
(x)=Different from VCD, (x)=p<0.05, (xx)=p<0.01, (xxx)=p<0.001 
A significant decrease was observed in endometrial 
thickness of VCD-treated groups compared to the control 
group (p<0.001). 17alphaEE, RES10 and 17betaE 
significantly reversed the effects of VCD (p<0.001). TMX 
did not alter the effects of RES (p<0.01) (Figs. 2, 9). 17betaE 
(p<0.05) and RES combined with TMX (p<0.01) significantly 
increased serum estradiol levels in peripubertal rats with POF 
(Fig. 10). There were no significant differences in serum 25 
hydroxy vitamin D levels and bone mineral density in none of 
the groups of the peripubertal rats with POF.
Fig. 9. Histologic Scores of peripubertal female rats with POF (Ba-
sed on endometrial thickness) (n=6)
(*)=Different from control, (***)=p<0.001   
(x)=Different from VCD, (xxx)=p<0.001
(^)= Different from VCD+17 alpha EE, (^^^)=p<0.001
(+)=Different from VCD+Res10, (+++)=p<0.001
Fig. 10. Serum estradiol levels in peripubertal rats with POF (n=6)
(*)=Different from control, (*)=p<0.05
(x)=Different from VCD, (x)=p<0.05, (xx)=p<0.01
(^)=Different from VCD+17 alpha EE, (^)=p<0.05
(+)=Different from VCD+RES 10, (+)=p<0.05
Discussion
In the present study, the putative estrogenic activity of RES 
was evaluated in immature rats and peripubertal rats with 
POF  induced by VCD. It was found that RES increased 
UW/BW as much as that resulted by the administration of 
17alphaEE. This activity was not decreased by the addition 
of TMX but decreased significantly by FLV Fig. 3.  TMX 
did not antagonize the effects of RES completely in female 
rats with POF (Fig. 7).
Growing evidence from preclinical studies suggests that 
RES may have the potential to affect a variety of human 
diseases in appositive manner.  It has been suggested that 
phytoestrogens may possess a weak estrogenic, selective 
estrogen modulating (SERM) or antiestrogenic effects 
[14]. In the presence of estradiol, such compounds may 
also have an antagonistic effect and decrease the potency 
of estradiol. It was suggested that the estrogenic potency 
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of phytoestrogens was lower as compared to endogenous 
or synthetic estrogens like 17betaE and 17alphaEE [15]. 
There are some differences in the potency of phytoestrogens 
and in the molecular mechanisms of their actions. Several 
phytoestrogens may show different affinities to different 
estrogen receptor subtypes of alpha and beta (ERa and ERb). 
The distribution of ERa and ERb in different tissues is the 
molecular basis of the tissue selective action of certain drugs. 
TMX is known to have antagonistic activity in the mammary 
gland, but to exhibit agonistic activity in the endometrium 
[16]. SERMS are known to have antiestrogenic activity 
in certain tissues like mammary and uterus and estrogenic 
activity in some tissues like brain, bone and cardiovascular 
cells [17]. Phytoestrogens may  also be expected to act in 
a tissue-specific manner. It was suggested that resveratrol 
have a mixed estrogen agonist/antagonist activity in some 
mammary cancer cell lines; but in the presence of estradiol, 
RES may act as an antiestrogenic compound [18]. It was also 
reported that RES showed antagonistic activity on ERa, but 
not on ERb  [19]. It was not clear that RES is an estrogenic 
agonist or antagonist [20].
In the present study, we noticed that RES has a dose-
dependent uterotrophic activity as that of 17alphaEE 
(Fig. 3). It was interesting that the combination of RES2 
and 17alphaEE inhibited the effects of 17alphaEE on 
endometrial thickness. It seems that RES has an antagonistic 
effect on estrogenic agonist, 17alphaEE (Fig. 5). However, 
this activity was not observed macroscopically in UW/
BW. Another interesting result of the present study is that 
there was no significant change in the levels of estradiol 
in all groups except the group received RES20 (Fig. 6). 
The high dose of RES may inhibit estradiol production. It 
seems that this result may be related to the antiestrogenic 
activity of RES. We observed a significant change in UDW/
UWW only in the group that received a  combination of 
17alphaEE and FLV (Fig. 4). Increased UDW/UWW may 
reflect the cellular responses such as increased protein, DNA 
and uterine peroxidase levels [21]. It seems that FLV may 
have some inhibitory effects on rehydration of the uterine 
tissues. However, there was no change in protein synthesis. 
Likewise, CP-336,156, a nonsteroidal estrogen agonist/
antagonist has been suggested to have a number of effects 
on rehydration in uterine tissue which are not elucidated yet 
[11]. 
In the second step of the present study, we aimed to 
evaluate the possible beneficial effects of RES on the uterus 
of peripubertal rats with POF by using its dose (10 mg/
kg) that had minimal uterotrophic activity.  It was reported 
that VCD leads to selective destruction of primordial and 
primary follicles when administered to mice and rats by daily 
intraperitoneal injections [9]. RES was shown to scavenge 
hydroxyl radicals and superoxides and protect against lipid 
peroxidation in cell membranes and the ROS-related DNA 
damage [22]. In addition, it was reported that RES enhances 
intracellular antioxidant levels in cardiomyocytes and 
aortic muscle cells [23,24]. It was also indicated that RES 
has hepatoprotective effects and reduces oxidative stress in 
rats [25,26]. VCD is known as a lipophilic molecule and its 
absorption into systemic circulation results to a chemically 
induced inflammatory reaction [12]. It was reported that 
VCD is useful for perimenoposal studies and does not have 
long-term effects in nonovarian tissues [12]. We determined 
that VCD significantly inhibited UW/BW and RES and 
17betaE counteracted its effects (Fig. 7). RES and 17betaE 
also significantly increased body weights in the rats with 
POF and TMX did not inhibit the effect of RES (Fig. 8). 
In regard to the endometrial thickness, similar results were 
shown in (Fig. 9).  The uterine weight loss induced by 
VCD was attributed to the loss of trophic effects of ovarian 
17betaE on the uteri [27]. 17betaE and the combination 
of RES10 and TMX significantly increased the levels of 
estradiol (Fig. 10).  It seems that the changes in estradiol 
can affect appetite and body weight gain in these animals. 
Some changes were expected in serum levels of 25 hydroxy 
vitamin D and in bone mineral density in rats with POF. 
But no significant change was noticed in none of the groups. 
Taken together, these data suggest that this time period was 
not sufficient to induce osteoporotic changes. 
In conclusion, the results of the present study suggest 
that dose of RES may play an important role in its estrogenic 
activity.  It can also be thought that RES may have an 
estrogenic modulatory activity. Further studies are needed to 
clear the complete mechanism of the estrogenic modulatory 
activity of RES.
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